A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 26 Sep 2017
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
- Indications Breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 31 Aug 2017 Planned End Date changed from 1 May 2018 to 28 Feb 2019.
- 06 Jan 2017 Planned primary completion date changed from 1 Mar 2018 to 1 May 2018.
- 12 Dec 2016 Planned End Date changed from 1 Mar 2018 to 1 May 2018.